Value in Health
- About the Editors
- For Authors
- Issue Archives
- Editor's Choice
- Budget Impact
- Cardiovascular Disease
- Cost-Effectiveness Analysis
- Health Policy
- EQ-5D and Health-Related Quality of Life
- Multiple Criteria Decision Analysis
- Personalized Medicine
- Value and Pricing
- Value in Health Regional Issues
- Value & Outcomes Spotlight
- Value in Health
- Therapeutic and Diagnostic Device Outcomes Research
- Reliability and Validity of Data Sources for Outcomes Research & Disease and Health Management Programs
- ISPOR Taxonomy of Patient Registries: Classification, Characteristics and Terms
- Healthcare Cost, Quality and Outcomes: ISPOR Book of Terms
- All ISPOR Bookstore Items
- Advertising & Sponsorship
The diagnosis of Alzheimer’s disease (AD) remains difficult. Lack of diagnostic certainty or possible distress related to a positive result from diagnostic testing could limit the application of new testing technologies. The objective of this paper is to quantify respondents’ preferences for obtaining AD diagnostic tests and to estimate the perceived value of AD test information.
Discrete-choice experiment and contingent-valuation questions were administered to respondents in Germany and the United Kingdom. Choice data were analyzed by using random-parameters logit. A probit model characterized respondents who were not willing to take a test.
Most respondents indicated a positive value for AD diagnostic test information. Respondents who indicated an interest in testing preferred brain imaging without the use of radioactive markers. German respondents had relatively lower money-equivalent values for test features compared with respondents in the United Kingdom.
Respondents preferred less invasive diagnostic procedures and tests with higher accuracy and expressed a willingness to pay up to €700 to receive a less invasive test with the highest accuracy.
Axel Mühlbacher F. Reed Johnson Jui-Chen Yang Michael Happich Mark Belger